Aug 2026
Paving the way for immunotherapy: Simvastatin-primed dual-targeting NPTAC overcomes immune resistance in hepatocellular carcinoma.
A "Pave the Way Strategy" combining simvastatin (SIM) with a dual-targeted nanoparticle-mediated targeting chimera (Hs/αPD-L1-NPTAC) enables precise HCC targeting and synchronous intracellular functions and provides a promising approach to overcome ICB resistance and enable precision immunotherapy for HCC.
Chen Chen, Quanwei Sun, Qiong-Liu Yu et al.
· Biomaterials · 0 citations